News Minerva Neurosciences, Inc.

Equities

NERV

US6033802058

Real-time Estimate Cboe BZX Other stock markets 02:56:32 2024-04-18 pm EDT			5-day change	1st Jan Change
2.49 ^USD	+0.81%		-1.57%	-59.35%

Feb. 27	Sector Update: Health Care Stocks Ease Late Afternoon	MT
Feb. 27	Top Midday Decliners	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Ease Late Afternoon	Feb. 27	MT
Top Midday Decliners	Feb. 27	MT
Sector Update: Health Care Stocks Decline Tuesday Afternoon	Feb. 27	MT
Minerva Neurosciences Shares Tumble After FDA Rejects Roluperidone for Schizophrenia.	Feb. 27	MT
Minerva Neurosciences Shares Slide on Latest FDA Roluperidone Setback	Feb. 27	DJ
FDA Turns Away Minerva's Roluperidone Schizophrenia Drug	Feb. 27	DJ
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia	Feb. 27	CI
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia	Feb. 27	AQ
Minerva Neurosciences: Q4 Earnings Snapshot	Feb. 22	AQ
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates	Feb. 22	AQ
Minerva Neurosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Minerva Neurosciences: Q3 Earnings Snapshot	Nov. 07	AQ
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates	Nov. 07	AQ
Minerva Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Minerva Neurosciences : Aug 15, 2023	23-08-15	PU
HC Wainwright Adjusts Price Target on Minerva Neurosciences to $11 From $8, Maintains Neutral Rating	23-08-02	MT
Minerva Neurosciences: Q2 Earnings Snapshot	23-08-01	AQ
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates	23-08-01	AQ
Minerva Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Minerva Neurosciences, Inc.

Equities

NERV

US6033802058

Summary

Filters